

Company Update

June 30, 2015

TICKER	NASDAQ: ORMP
RATING	BUY
PRICE TARGET	\$30.00
Price (June 29, 2015)	\$5.63

Oramed Pharmaceuticals, Inc.

First Patient Enters Phase IIb ORMD-0801 Trial

Market Data

Market Cap (M):	\$65.0
Shares out (M):	11.6
Float (M):	9.8
Daily Vol, 3 Mo Avg (M):	0.2
52-Week Range:	\$10.44-\$3.71
Cash & Cash Eq (M):	\$1.1
Debt (M):	\$0.0
NAV (M):	NA

Cash includes short term investments, restricted cash, and deposits.

Financial Metrics

Short Interest (M):	0.7
Instit. Holdings (%):	13.0%
Cash Burn (M):	NA
Short Interest (% of Float):	8.8%

EPS	1Q	2Q	3Q	4Q	FY
2013	-0.16A	-0.17A	-0.17A	-0.17A	-0.59A
2014	-0.17A	-0.12A	-0.18A	-0.17A	-0.62A
2015	-0.19A	-0.15A	-0.18E	-0.21E	-0.72E

Note: Historical quarterly EPS figures may not add up, due to a 1:12 reverse stock split that took place in 2013.

1-Year Price History



Created by BlueMatrix

This morning, Oramed reported that the first patient in its Phase IIb trial of ORMD-0801, an oral insulin capsule formulation, had been successfully screened. In our view, this represents a significant clinical development milestone for the company. Investors should be aware that this Phase IIb study could report data early next year, depending upon the pace of enrollment, and that Oramed is fully funded through the completion of this trial. We reiterate our BUY rating and 12-month price target of \$30 per share.

- Phase IIb Trial Starts On Schedule.** We note that the announcement of the first patient being screened comes in-line with the company's previously-announced timeline, and signals the positive review of the trial protocol by the FDA. The current Phase IIb trial is slated to enroll roughly 180 subjects with Type II diabetes across approximately 30 clinical sites in the United States, and should in our view generate the kind of data that potential collaborators would find compelling, if successful.
- Significant Market Opportunity.** Type II diabetics accounts for 95% of the market. An oral insulin pill at bedtime would be a particularly attractive way of controlling fasting glucose levels in Type II patients who have not yet transitioned to injectable insulin. On positive Phase IIb data, we expect a potential partnership and Phase III initiation by early 2017.
- Other Upcoming Catalysts.** Oramed's second pipeline candidate, ORMD-0901, could also move into a Phase IIb trial later this year. We note that ORMD-0801 and ORMD-0901 could be used in combination as well. Oramed recently reported that it was granted a patent in Russia covering methods and compositions for administration of oral exenatide, the active agent in ORMD-0901.

RAGHURAM SELVARAJU, PH.D.
rselvaraju@mlvco.com

Senior Analyst
212-542-5868

IMPORTANT DISCLOSURES AND CERTIFICATIONS.

MLV & Co LLC is a provider of research and execution services. MLV is a member of FINRA. MLV does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Please see important disclosures on page 4 - 6.

VALUATION

Our PT is based on a DCF of ORMD-0801 and ORMD-0901 taken out to 2030, using a 10-15% discount rate and probabilities of success of 80% and 60%, respectively.

INVESTMENT RISK

Risks include: negative clinical trial data for either ORMD-0801 or ORMD-0901, failure to obtain strong US IP, any regulatory delays/setbacks, and dilutive financings.

FINANCIAL STATEMENTS

Exhibit 1: Income Statement – Annual with Projections

Income Statement (\$000)	FY 2013A	FY 2014A	F1QA Nov 30	F2QA Feb 28	F3QE May 31	F4QE Aug 31	FY 2015E	FY 2016E	FY 2017E	FY 2018E	FY 2019E	FY 2020E
ORMD0801 T2D royalty revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ORMD0901 royalty revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	41,543.4
ORMD0801 milestone revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50,000.0	0.0	75,000.0	0.0
ORMD0901 milestone revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	30,000.0	0.0	50,000.0
Total revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50,000.0	30,000.0	75,000.0	91,543.4
COGS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50,000.0	30,000.0	75,000.0	91,543.4
R&D	2,271.8	3,277.0	1,302.0	1,136.0	1,400.0	1,600.0	5,438.0	6,500	8,500	11,000	6,500	5,500
SG&A	2,032.1	2,629.0	600.0	538.0	650.0	800.0	2,588.0	3,200	4,000	5,000	6,500	7,500
Operating profit	(4,303.9)	(5,906.0)	(1,902.0)	(1,674.0)	(2,050.0)	(2,400.0)	(8,026.0)	(9,700.0)	37,500.0	14,000.0	62,000.0	78,543.4
Financial income	180.5	223.6	27.0	38.0	0.0	0.0	65.0	0.0	0.0	0.0	0.0	0.0
Financial expense	313.4	9.6	21.0	1.0	0.0	0.0	22.0	0.0	0.0	0.0	0.0	0.0
Pre-tax profit (loss)	(4,436.9)	(5,692.0)	(1,896.0)	(1,637.0)	(2,050.0)	(2,400.0)	(7,983.0)	(9,700.0)	37,500.0	14,000.0	62,000.0	78,543.4
Tax	0.0	4.0	0.0	0.0	0.0	0.0	0.0	(2,570.5)	9,937.5	3,710.0	16,430.0	20,814.0
Other items, net	(303.4)	0.0	359.0	(7.0)	0.0	0.0	352.0	0.0	0.0	0.0	0.0	0.0
Net Income (loss)	(4,133.5)	(5,696.0)	(2,255.0)	(1,630.0)	(2,050.0)	(2,400.0)	(8,335.0)	(7,129.5)	27,562.5	10,290.0	45,570.0	57,729.4
Diluted EPS	(\$0.59)	(\$0.62)	(\$0.19)	(\$0.15)	(\$0.18)	(\$0.21)	(\$0.72)	(\$0.60)	\$1.87	\$0.70	\$3.09	\$3.91
Diluted Shares Out	7,209.3	9,244.1	10,142.0	10,826.1	11,181.3	11,538.6	11,538.6	11,895.9	14,753.3	14,753.3	14,753.3	14,753.3

Source: Company reports and MLV & Co. research


IMPORTANT DISCLOSURES**Analyst Certification**

The research analyst, Raghuram Selvaraju, Ph.D., who is primarily responsible for the preparation of this research report, certifies that (i) all views expressed in this research report accurately reflect the analyst's personal views about any and all the subject issuer and security featured in this report and (ii) no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Rating and Price Target History

MLV disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available upon request.

All required current disclosures on subject companies covered in this report may be obtained by contacting Charles Comer at MLV & Co. at 1301 Avenue of the Americas, 43rd Floor, New York, NY 10019 or ccomer@mlvco.com or 1 (888) 344-2272.

Oramed Pharmaceuticals, Inc. (ORMP): Share Price (in USD) and Volume History as of 06-29-2015**MLV RATING ALLOCATION (as of June 29, 2015)**

BUY: MLV projects that the subject company's stock price will increase in value by 20% or more in the next 12 months.

HOLD: MLV projects that the subject company's stock price will trade in a range not more than 20% above or below its current price.

SELL: MLV projects that the subject company's stock price will decrease in value by 20% or more in the next 12 months.

Rating	COMPANIES UNDER COVERAGE		INVESTMENT BANKING SERVICE WITHIN 12 MONTHS	
	Count	Percent	Count	Percent
BUY	126	69.23%	61	33.52%
HOLD	56	30.77%	15	8.24%
SELL	0	0.00%	0	0.00%

Issuer Specific Disclosures

MLV or any affiliate expects to receive or intends to seek compensation for investment banking services from Oramed Pharmaceuticals, Inc. in the next 3 months.

Additional Disclosures

The analyst primarily responsible for the preparation of this research report is a registered agent of MLV & Co LLC. An analyst or a member of its household may not purchase the securities of a subject company 30 days before or 5 days after the issuance of a research report or a change in ratings or price target, trade inconsistent with the views expressed by the research analyst, and all transactions in a research analyst's personal trading must be pre-approved. Neither the research analyst nor a member of his or her household may own any securities of the subject company based on the same standards used to compute beneficial ownership for the purpose of reporting requirements under 13(d) of the Securities Act of 1934. The research analyst has not made a public appearance in front of more than 15 persons to discuss the subject company and does not know or have reason to know at the time of this publication of any other material conflict of interest. Neither MLV nor its research analysts have any knowledge of any material conflict of interest involving the company(ies) mentioned in this report and the firm. Research analysts at MLV do not receive any compensation based on investment banking revenues.

MLV is a U.S. registered broker-dealer and member of the FINRA and SIPC. This research report is prepared for institutional and other qualified investors. The information herein does not constitute a solicitation of an offer to buy or an offer to sell any security nor is it intended to be a complete summary or statement of all available data. This report is not produced based on any individual entities investment objectives or financial situation and opinions contained herein are subject to change without notice and reflect our judgment on the date of this report. Any opinions, estimates or projections expressed in this report may assume some economic industry and political considerations and constitute current opinions, at the time of issuance, and are subject to change. Calculations of price targets are based on a combination of one or more methodologies generally accepted among financial analysts, including but not limited to, analysis of multiples and/or discounted cash flows (whether whole or in part), or any other method which may be applied. Any estimates or forecasts contained in this report may not be met and past performance is not an indication of future results. Rating, target price and price history information on the subject company in this report is available upon request.

The securities discussed in this report are speculative and not suitable for all investors. Investors should consider this report as only a single factor in making their investment decision and should make their own decision based on their specific financial situation and investment objectives. As with any transaction having tax implications, investors should consult with their tax advisor before making investment decisions designed to generate tax benefits. As a matter of policy MLV does not offer tax advice and nothing herein should be construed as offering such advice.

Although the statements of fact in this report have been obtained from and are based upon outside sources that MLV believes to be reliable, MLV does not guarantee the accuracy or completeness of material contained in this report. The value of this security is subject to many variables, including, but not limited to, capital market conditions, interest rates, competition, regulatory environment and clinical trial results. Securities prices fluctuate and investors may receive back less than originally invested and are not guaranteed. The securities recommended, offered, or sold by the firm, are not insured by the Federal Deposit Insurance Corporation, are not deposits or other obligations of any insured depository institution, and are subject to risks, including the possible loss of principal amount invested.

OTHER IMPORTANT INFORMATION

No part of this document may be copied, photocopied, or duplicated in any form or other means redistributed or quoted without the prior written consent of MLV & Co LLC.

To receive any additional information upon which this report is based, including disclosures please contact MLV at 212-542-5880 or write to: Research Department, MLV & Co LLC, 1301 Avenue of the Americas, 43rd Floor, New York, NY 10019.

Copyright 2015 MLV & Co LLC. All rights reserved.

LOCATIONS**New York**

1301 Avenue of the Americas
43rd Floor
New York, NY 10019
212-542-5880

Denver

399 Perry Street
Suite 204A
Castle Rock, CO 80104
212-317-1577

Houston

520 Post Oak Blvd
Suite 850
Houston, TX 77027
832-208-2030

CONTACT INFORMATION**Research | Healthcare**

Arlinda Lee, Ph.D.
alee@mlvco.com
646-412-7701

Vernon T. Bernardino
vbernardino@mlvco.com
646-412-7675

Raghuram Selvaraju, Ph.D.
rselvaraju@mlvco.com
212-542-5868

Ken Trbovich
ktrbovich@mlvco.com
212-317-1577

Ben Shim
bshim@mlvco.com
646-412-7703

Thomas Yip
tyip@mlvco.com
212-542-5876

Sales and Trading

Scott Ammaturo
sammatturo@mlvco.com
646-556-9218

Christian Moscicki
cmoscicki@mlvco.com
646-412-7697